Studies from Oregon Health & Science University (OHSU) Provide New Data on Lung Cancer (Angiotensin receptor blockade and stereotactic body radiation therapy for early stage lung cancer ARB & SBRT for early stage lung cancer).

A study conducted by Oregon Health & Science University (OHSU) investigated the use of angiotensin receptor blockade (ARB) in combination with stereotactic body radiation therapy (SBRT) for early stage lung cancer. The study found that patients taking ARBs during SBRT exhibited improved overall survival (OS) and recurrence-free survival (RFS) compared to patients not taking ARBs. However, the same effects were not observed in patients taking angiotensin converting enzyme inhibitors (ACEIs) or statins. These findings suggest that ARB use during SBRT may be beneficial for patients with early stage lung cancer. [Extracted from the article]